Company intelligence / Profile preview

Poietis

Pessac, Nouvelle-Aquitaine, France

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Poietis is a French health-tech company developing and commercializing 4D bioprinting platforms for advanced tissue engineering, with the world's first clinical trial of a bioprinted skin graft (dermo-epidermal substitute) initiated in 2022 at the University Hospital of Marseille. The NGB platform offers high-resolution, versatile, and automated tissue manufacturing for research and clinical applications, aiming to address unmet needs in regenerative medicine, pharmaceutical testing, and cosmetics[1][4][6].

Therapeutic areas: OtherOphthalmologyDermatologyRheumatology
Modalities: Cell therapyTissue engineering
Industry: Biotech

Drug pipeline

1 asset

Poieskin

Partnerships

University Hospital of Marseille (AP-HM)Stäubli (robotics)

Beyond the preview

Go deeper on Poietis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poietis.

Explore the full profile